Eps8 peptide 327

Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models[1].

1988684-26-9

Eps8 (327-335)

12352209

Apoptosis; Complement System; EGFR; IFNAR; Interleukin Related; TNF Receptor

Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

COVID-19-immunoregulation

Cancer; Inflammation/Immunology

O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CS)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=CC=C3)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N

C56H77N11O15S

1176.34

[1]Xie X, et al. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8) -derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. Cell Death Dis. 2018 Mar 7;9 (3) :379.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10994/

Peptides

No Development Reported

IL-2